Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (6115)	2/14/2001 9:56:18 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 6136

Some old-timers might enjoy this? Emphasis mine........ Monday February 12, 8:05 am Eastern Time Press Release SOURCE: ViroPharma Incorporated ViroPharma Incorporated Announces Election of Paul A. Brooke To Board of Directors EXTON, Pa., Feb. 12 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM - news) announced today the election of Paul A. Brooke to its board of directors. Mr. Brooke currently is a managing member of PMSV Holdings LLC, a partner of MPM Bioventures and an advisory director for Morgan Stanley Dean Witter. Mr. Brooke has spent more than 25 years in the investment industry, specializing in healthcare, and has served as an advisor on a number of initial public offerings, corporate restructurings and mergers and acquisitions. Most recently, he was a managing director at Tiger Management LLC. Prior to that, he was a managing director at Morgan Stanley Dean Witter and was global head of healthcare research and strategy. ``Paul brings tremendous talent and expertise to ViroPharma's board of directors,'' said Michel de Rosen, ViroPharma's president and chief executive officer. ``His extraordinary experience, relationships and knowledge about our industry will be an extremely valuable asset to us as we continue to develop and implement ViroPharma's business strategy in the coming years.'' ViroPharma Incorporated is committed to the commercialization, development and discovery of antiviral pharmaceuticals. The company is focused on drug development and discovery activities for viral diseases, including viral respiratory infection (VRI), hepatitis C and RSV disease. ViroPharma's most advanced product candidate, pleconaril, is in clinical development for the treatment of picornavirus diseases, including late stage clinical trials for VRI. ViroPharma also has product candidates in clinical trials for the treatment of hepatitis C and RSV disease. SOURCE: ViroPharma Incorporated